Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients.

Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik BA, Nyirády P, Szendröi A, Szücs M, Módos O, Olah C, Székely E, Reis H, Szarvas T.

Pathol Oncol Res. 2019 Jun 27. doi: 10.1007/s12253-019-00689-y. [Epub ahead of print]

PMID:
31250373
2.

[Predictive biomarkers in oncologic uropathology].

Reis H, Szarvas T, Grünwald V.

Pathologe. 2019 May;40(3):264-275. doi: 10.1007/s00292-019-0606-3. Review. German.

PMID:
31073639
3.

Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.

Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T.

Urol Oncol. 2019 Apr 30. pii: S1078-1439(19)30148-6. doi: 10.1016/j.urolonc.2019.04.015. [Epub ahead of print]

PMID:
31053526
4.

High soluble CGA levels are associated with poor survival in bladder cancer.

Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirady P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H.

Endocr Connect. 2019 Apr 1. pii: EC-19-0068.R1. doi: 10.1530/EC-19-0068. [Epub ahead of print]

5.

Urachal cancer-current concepts of a rare cancer.

Reis H, Szarvas T.

Pathologe. 2019 Jun;40(Suppl 1):31-39. doi: 10.1007/s00292-018-0516-9. Review.

PMID:
30895340
6.

Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood.

Maj-Hes A, Sevcenco S, Szarvas T, Kramer G.

Adv Ther. 2019 Apr;36(4):916-922. doi: 10.1007/s12325-019-0888-0. Epub 2019 Feb 18.

PMID:
30778908
7.

[Molecular subtypes and perspectives of targeted therapies in prostate cancer].

Szarvas T, Csizmarik A, Szűcs M, Nyirády P.

Orv Hetil. 2019 Feb;160(7):252-263. doi: 10.1556/650.2019.31315. Hungarian.

PMID:
30741006
8.

ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer.

Küronya Z, Sükösd F, Varga L, Bíró K, Gyergyay F, Géczi L, Nagyiványi K, Jorgo K, Szarvas T, Kovács Á, Laczó I, Varga Z, Pósfai B, Pepó J, Maráz A.

Urol Oncol. 2019 Apr;37(4):289.e1-289.e9. doi: 10.1016/j.urolonc.2018.12.007. Epub 2019 Jan 21.

PMID:
30679082
9.

Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.

Tschirdewahn S, Panic A, Püllen L, Harke NN, Hadaschik B, Riesz P, Horváth A, Szalontai J, Nyirády P, Baba HA, Reis H, Szarvas T.

Int J Cancer. 2019 Jul 15;145(2):531-539. doi: 10.1002/ijc.32124. Epub 2019 Jan 31.

PMID:
30650187
10.

[Urachal cancer - current concepts of a rare cancer (German version)].

Reis H, Szarvas T.

Pathologe. 2018 Dec;39(Suppl 2):291-300. doi: 10.1007/s00292-018-0498-7. Review. German.

PMID:
30470871
11.

Uric Acid Control in Advanced Chronic Kidney Disease in a Southeastern US Urban Cohort.

Fülöp T, Koch CA, Norris LT, Rodríguez B, Szarvas T, Lengvárszky Z, Csongrádi É, Dixit MP.

South Med J. 2018 Sep;111(9):549-555. doi: 10.14423/SMJ.0000000000000862.

PMID:
30180253
12.

Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer.

Krafft U, Reis H, Ingenwerth M, Kovalszky I, Becker M, Niedworok C, Darr C, Nyirády P, Hadaschik B, Szarvas T.

Pathol Oncol Res. 2018 Jul 17. doi: 10.1007/s12253-018-0447-z. [Epub ahead of print]

PMID:
30019121
13.

The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer.

Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, Shariat SF, Kramer G, Szarvas T.

Urol Int. 2018;101(1):65-73. doi: 10.1159/000489891. Epub 2018 Jun 27.

PMID:
29949801
14.

Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.

Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G.

BJU Int. 2018 Oct;122(4):695-704. doi: 10.1111/bju.14415. Epub 2018 Jun 20.

PMID:
29802777
15.

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Reis H, Krafft U, Niedworok C, Módos O, Herold T, Behrendt M, Al-Ahmadie H, Hadaschik B, Nyirady P, Szarvas T.

Dis Markers. 2018 Mar 12;2018:7308168. doi: 10.1155/2018/7308168. eCollection 2018. Review.

16.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

17.

Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.

Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, Shariat SF, Kramer G.

Urol Oncol. 2018 Jun;36(6):312.e9-312.e15. doi: 10.1016/j.urolonc.2018.03.010. Epub 2018 Apr 5.

PMID:
29628317
18.

Erratum to: Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma.

Szarvas T, Nyirády P, Ogawa O, Furuya H, Rosser CJ, Kobayashi T.

Methods Mol Biol. 2018;1655:E1. doi: 10.1007/978-1-4939-7234-0_25. No abstract available.

PMID:
29442339
19.

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.

Thiem S, Herold T, Krafft U, Bremmer F, Tolkach Y, Szász AM, Kriegsmann J, Gaisa NT, Niedworok C, Szarvas T, Reis H.

Pathol Int. 2017 Dec;67(12):597-601. doi: 10.1111/pin.12594. Epub 2017 Oct 19.

PMID:
29047227
20.

Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma.

Szarvas T, Nyirády P, Ogawa O, Furuya H, Rosser CJ, Kobayashi T.

Methods Mol Biol. 2018;1655:251-273. doi: 10.1007/978-1-4939-7234-0_19. Review. Erratum in: Methods Mol Biol. 2018;1655:E1.

PMID:
28889391
21.

Response to: Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma.

Reis H, Niedworok C, Szarvas T.

Pathology. 2017 Aug;49(5):561-562. doi: 10.1016/j.pathol.2017.04.006. Epub 2017 Jun 28. No abstract available.

PMID:
28666639
22.

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.

Droop J, Szarvas T, Schulz WA, Niedworok C, Niegisch G, Scheckenbach K, Hoffmann MJ.

PLoS One. 2017 Apr 21;12(4):e0176287. doi: 10.1371/journal.pone.0176287. eCollection 2017.

23.

Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival.

Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szücs M, Nyirády P, Romics I, Rübben H, Szarvas T.

Pathol Oncol Res. 2017 Jul;23(3):643-650. doi: 10.1007/s12253-016-0171-5. Epub 2016 Dec 23.

PMID:
28012116
24.

Why are upper tract urothelial carcinoma two different diseases?

Szarvas T, Módos O, Horváth A, Nyirády P.

Transl Androl Urol. 2016 Oct;5(5):636-647. Review.

25.

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.

Módos O, Reis H, Niedworok C, Rübben H, Szendröi A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, Shariat SF, Hollósi P, Nyirády P, Szarvas T.

Oncotarget. 2016 Jun 28;7(26):39293-39301. doi: 10.18632/oncotarget.9828.

26.

Response of Hepatic Stellate Cells to TGFB1 Differs from the Response of Myofibroblasts. Decorin Protects against the Action of Growth Factor.

Fullár A, Firneisz G, Regős E, Dudás J, Szarvas T, Baghy K, Ramadori G, Kovalszky I.

Pathol Oncol Res. 2017 Apr;23(2):287-294. doi: 10.1007/s12253-016-0095-0. Epub 2016 Aug 5.

PMID:
27495255
27.

Clinical Sequencing-guided Therapy of Urachal Carcinoma: New Perspective for a Rare Cancer.

Nyirády P, Niedworok C, Reis H, Szarvas T.

Eur Urol. 2016 Nov;70(5):776-777. doi: 10.1016/j.eururo.2016.07.004. Epub 2016 Jul 14. No abstract available.

PMID:
27423504
28.

Clinical Utility of Potassium-Sparing Diuretics to Maintain Normal Serum Potassium in Peritoneal Dialysis Patients.

Fülöp T, Zsom L, Rodríguez B, Afshan S, Davidson JV, Szarvas T, Dixit MP, Tapolyai MB, Rosivall L.

Perit Dial Int. 2017 1-2;37(1):63-69. doi: 10.3747/pdi.2016.00022. Epub 2016 Jun 9.

PMID:
27282853
29.

Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases.

Szarvas T, Módos O, Niedworok C, Reis H, Szendröi A, Szász MA, Nyirády P.

Urol Oncol. 2016 Sep;34(9):388-98. doi: 10.1016/j.urolonc.2016.04.012. Epub 2016 Jun 3. Review.

PMID:
27267737
30.

The effect of ambient temperature and humidity on interdialytic weight gains in end-stage renal disease patients on maintenance hemodialysis.

Tapolyai MB, Faludi M, Berta K, Szarvas T, Lengvárszky Z, Molnar MZ, Dossabhoy NR, Fülöp T.

Int Urol Nephrol. 2016 Jul;48(7):1171-6. doi: 10.1007/s11255-016-1297-9. Epub 2016 Apr 28.

PMID:
27126356
31.

Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.

Szarvas T, Reis H, Vom Dorp F, Tschirdewahn S, Niedworok C, Nyirady P, Schmid KW, Rübben H, Kovalszky I.

Prostate. 2016 Aug;76(11):977-85. doi: 10.1002/pros.23186. Epub 2016 Apr 7.

PMID:
27062540
32.

Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method.

Niedworok C, vom Dorp F, Tschirdewahn S, Rübben H, Reis H, Szucs M, Szarvas T.

Int Urol Nephrol. 2016 Mar;48(3):355-61. doi: 10.1007/s11255-015-1185-8. Epub 2016 Jan 2.

PMID:
26725072
33.

Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis.

Niedworok C, Panitz M, Szarvas T, Reis H, Reis AC, Szendröi A, Nyirády P, Szasz AM, Módos O, Rübben H, Vom Dorp F.

J Urol. 2016 Jun;195(6):1690-6. doi: 10.1016/j.juro.2015.11.067. Epub 2015 Dec 8.

PMID:
26678957
34.

Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors.

Hoffmann MJ, Dehn J, Droop J, Niegisch G, Niedworok C, Szarvas T, Schulz WA.

Noncoding RNA. 2015 Dec 17;1(3):266-284. doi: 10.3390/ncrna1030266.

35.

Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer.

Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T.

J Urol. 2016 Apr;195(4 Pt 1):1120-5. doi: 10.1016/j.juro.2015.09.084. Epub 2015 Oct 8.

PMID:
26454102
36.

Current State of ERG as Biomarker in Prostatic Adenocarcinoma.

Acs B, Szarvas T, Szekely N, Nyirady P, Szasz AM.

Curr Cancer Drug Targets. 2015;15(8):643-51. Review.

PMID:
26452381
37.

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.

Heubach J, Monsior J, Deenen R, Niegisch G, Szarvas T, Niedworok C, Schulz WA, Hoffmann MJ.

Mol Cancer. 2015 May 21;14:108. doi: 10.1186/s12943-015-0371-8.

38.

Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters.

Niedworok C, Dörrenhaus B, Vom Dorp F, Piotrowski JA, Tschirdewahn S, Szarvas T, Rübben H, Schenck M.

World J Urol. 2015 Oct;33(10):1541-52. doi: 10.1007/s00345-014-1449-4. Epub 2014 Nov 30.

PMID:
25433505
39.

Diuretics and bioimpedance-measured fluid spaces in hypertensive patients.

Tapolyai M, Faludi M, Dossabhoy NR, Barna I, Lengvárszky Z, Szarvas T, Berta K, Fülöp T.

J Clin Hypertens (Greenwich). 2014 Dec;16(12):895-9. doi: 10.1111/jch.12428. Epub 2014 Oct 20.

40.

Quantitative apparent diffusion coefficient measurements obtained by 3-Tesla MRI are correlated with biomarkers of bladder cancer proliferative activity.

Sevcenco S, Haitel A, Ponhold L, Susani M, Fajkovic H, Shariat SF, Hiess M, Spick C, Szarvas T, Baltzer PA.

PLoS One. 2014 Sep 9;9(9):e106866. doi: 10.1371/journal.pone.0106866. eCollection 2014.

41.

[Transitional cell carcinoma of the bladder: bladder-sparing therapy].

Vom Dorp F, Tschirdewahn S, Szarvas T, Rübben H, Kraemer R, Rehme C.

Urologe A. 2014 Sep;53(9):1322-8. doi: 10.1007/s00120-014-3554-9. German. Erratum in: Urologe A. 2014 Dec;53(12):1804. Kraemer, R [added].

PMID:
25148911
42.

Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness.

Sevcenco S, Ponhold L, Heinz-Peer G, Fajkovic H, Haitel A, Susani M, Shariat SF, Szarvas T, Baltzer PA.

Urol Oncol. 2014 Nov;32(8):1166-71. doi: 10.1016/j.urolonc.2014.04.019. Epub 2014 Jun 21.

PMID:
24962659
43.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.

44.

Prognostic effect of serum and tissue YKL-40 levels in bladder cancer.

Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T.

Urol Oncol. 2014 Jul;32(5):663-9. doi: 10.1016/j.urolonc.2014.02.004. Epub 2014 May 9.

PMID:
24814404
46.

Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.

Szarvas T, Reis H, Kramer G, Shariat SF, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübben H.

Hum Pathol. 2014 Apr;45(4):674-82. doi: 10.1016/j.humpath.2013.10.036. Epub 2013 Dec 18.

PMID:
24656090
47.
48.

Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.

Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, Shariat SF, Rübben H, vom Dorp F.

Int J Cancer. 2014 Oct 1;135(7):1596-604. doi: 10.1002/ijc.28808. Epub 2014 Mar 4.

49.

Reply by the authors.

Kuehhas FE, Sharma V, Sevcenco S, Javadli E, Herwig R, Szarvas T, Schatzl G, Weibl P, Miernik A, Schoenthaler M.

Urology. 2013 Nov;82(5):1192-3. No abstract available.

PMID:
24358500
50.

Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.

Niedworok C, Röck K, Kretschmer I, Freudenberger T, Nagy N, Szarvas T, Vom Dorp F, Reis H, Rübben H, Fischer JW.

PLoS One. 2013 Nov 6;8(11):e80084. doi: 10.1371/journal.pone.0080084. eCollection 2013.

Supplemental Content

Loading ...
Support Center